Stocksigma LogoStocksigma Logo

Remus Pharmaceuticals Board to Consider H1 FY27 Results and Interim Dividend

Remus Pharmaceuticals Limited has scheduled a Board of Directors meeting for 3rd Nov'26. The board will consider and approve the unaudited standalone and

Remus Pharmaceuticals Board to Consider H1 FY27 Results and Interim Dividend

Remus Pharmaceuticals Ltd 路 Intimation 路 03 Nov 2026, 5:30 am

Remus Pharmaceuticals Board to Consider H1 FY27 Results and Interim Dividend Remus Pharmaceuticals Limited has scheduled a Board of Directors meeting for 3rd Nov'26. The board will consider and approve the unaudited standalone and consolidated financial results for the half-year ended 30th Sep'26, accompanied by the limited review report. Additionally, the board will evaluate a proposal to declare a 1st interim dividend on equity shares for FY27. In compliance with insider trading regulations, the trading window for dealing in company securities remains closed from 1st Oct'26 until 48 hours post-result declaration.

Original exchange filing (PDF)

More announcements from Remus Pharmaceuticals Ltd

All Remus Pharmaceuticals Ltd announcements